nach oben

Drugs

Erschienen in:

01.03.2015 | Adis Drug Evaluation

Naloxegol: A Review of Its Use in Patients with Opioid-Induced Constipation

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Oral naloxegol (Movantik™, Moventig^®), a peripherally acting μ-opioid receptor antagonist, inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract. This article reviews the pharmacological properties of naloxegol and its clinical efficacy and tolerability in patients with opioid-induced constipation. It demonstrated clinical efficacy and was well tolerated in placebo-controlled trials in patients with non-cancer pain and opioid-induced constipation, including those with an inadequate response to laxatives, and was well tolerated in a long-term safety study. As a PEGylated naloxone derivative, naloxegol is associated with significant improvements in spontaneous bowel movements, while maintaining levels of opioid-related analgesia (a result of its reduced ability to cross the blood-brain barrier). Naloxegol is a useful option in the treatment of opioid-induced constipation.

Brock C, Olesen S, Olesen A, et al. Opioid-Induced Bowel Dysfunction. Drugs. 2012;72(14):1847–65.CrossRefPubMed

Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386–95.CrossRefPubMed

AstraZeneca. Movantik™ (naloxegol tablets): US prescribing information. 2014. http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=movantik&country=us&popup=no. Accessed 23 Jan 2015.

European Medicines Agency. Moventig® (naloxegol oxalate tablets): EU summary of product characterisitics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002810/WC500179075.pdf. Accessed 23 Jan 2015.

AstraZeneca. Naloxegol (NDA 204-760) Briefing Document for the Anesthetic and Analgesic Drug Products Advisory Committee. 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm400209.pdf. Accessed 27 Nov 2014.

Eldon M, Song D, Neumann TA, et al. NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical models [abstract no. 28 plus poster]. In: 18th annual clinical meeting of the American Academy of Pain Management. 2007.

Neumann TA, et al. Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral Opioid Antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study [abstract no. II-36]. In: 36th annual meeting of the American College of Clinical Pharmacology. 2007.

Odinecs A, Gadiraju R, Sisco J, et al. Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug [abstract no. 140]. J Clin Pharmacol. 2009;49(9):1123.

Gottfridsson C, Carlson G, Lappalainen J, et al. Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther. 2013;35(12):1876–83.CrossRefPubMed

10.

Bui KH, Hutchison M, Brunnstrom A, et al. Absorption, Metabolism and Excretion of [14C]-Naloxegol in Human Subjects [abstract no. R6319 plus poster]. In: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. 2013.

11.

Sahner D, van Paaschen H, et al. Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118 [abstract no. 210 plus poster]. J Pain. 2008;9(4 Suppl 2):P28.CrossRef

12.

Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014. doi:10.1002/jcph.348.

13.

Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;. doi:10.1002/jcph.349.

14.

Bui K, Zhou D, Sostek M, et al. Effects of CYP3A modulators on the PK of naloxegol [abstract no. PI-108]. Clin Pharmacol Ther. 2014;95(Suppl. 1):S53.

15.

Bui KH, She F, Zhou D, et al. Evaluation of the effect of quinidine, a strong Pgp inhibitor, on the pharmacokinetics and CNS distribution of naloxegol [abstract no. 1710175]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):8–9.

16.

Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542–50.CrossRefPubMed

17.

Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–96.CrossRefPubMed

18.

Chey W, Tack J, Webster L, et al. Efficacy of naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from two, prospective, randomized controlled trials [abstract no. 1884]. Am J Gastroenterol. 2013;108(Suppl. 1):S570.

19.

Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771–9.CrossRefPubMed

20.

Von Roenn JH, Tack J, Barker PN, et al. Challenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation (OIC). Support Care Cancer. 2013;21:S259.

Titel: Naloxegol: A Review of Its Use in Patients with Opioid-Induced Constipation
verfasst von: Karly P. Garnock-Jones
Publikationsdatum: 01.03.2015
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 4/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-015-0357-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

Vonoprazan: First Global Approval

Identification and Management of Alcohol Withdrawal Syndrome

Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections

Preventive Analgesia and Novel Strategies for the Prevention of Chronic Post-Surgical Pain

Fluticasone Furoate/Vilanterol: a Review of Its Use in Patients with Asthma